TenNor Therapeutics (Suzhou) (6872) investor relations material

Executive summary

• Achieved significant progress in product pipeline, with rifasutenizol entering supplementary review for H. pylori and rifaquizinone advancing in clinical trials.

• Completed IPO on the Hong Kong Stock Exchange, raising substantial capital for future development.

• No commercialized products yet; focus remains on R&D and regulatory milestones.

Financial highlights

• Loss for the period decreased to RMB64.2 million from RMB78.2 million year-over-year.

• Research and development expenses rose to RMB31.3 million, up RMB5.0 million year-over-year.

• Administrative expenses increased to RMB32.0 million, mainly due to listing expenses and share grants.

• Cash and cash equivalents surged to RMB714.7 million from RMB183.8 million, driven by IPO proceeds.

• No revenue generated from product sales during the period.

Outlook and guidance

• Plans to accelerate clinical development and commercialization of core products, especially rifasutenizol and rifaquizinone.

• Intends to expand indications and geographic reach, including U.S. and global markets.

• Ongoing construction of in-house manufacturing facility, expected operational in 2028.

• No interim dividend declared for the period.